AAWH · Ascend Wellness Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q1 FY26 earnings call · May 13, 2026TL;DR. AAWH reported Q1 2026 revenue of $116.9 million (down 3% sequentially) and Adjusted EBITDA of $26.3 million (margin 22.5%), beating guidance; the company guided to 2–3% Q2 revenue growth and held EBITDA margin in the low-20% range, while highlighting DOJ rescheduling of medical cannabis as a potential near-term tax (280E) benefit and ongoing margin expansion from rising verticality.
- + Q1 revenue and Adjusted EBITDA both came in ahead of guidance and market expectations.
- + Adjusted Gross Profit margin expanded 70 bps sequentially to 46.1% on improved verticality.
- + Retail footprint expansion is on track to grow from 51 to at least 60 stores by year-end, supporting topline growth.
- − Net revenue declined 3% sequentially to $116.9 million due to post-holiday softness and severe winter weather disruptions.
- − Adjusted EBITDA fell 12.9% sequentially to $26.3 million on lower sales absorption and rising SG&A.
- − Operations at the Lansing, Michigan cultivation facility are temporarily suspended for fire remediation.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $29.1M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss -$9.81M
-$5.72M Income tax (benefit) expense
+$6K Other expense (income), net
+$20.8M Interest expense
+$21.05M Depreciation and amortization
+$1.57M Non-cash inventory adjustments
+$879K Equity-based compensation
+$3.11M Start-up costs
-$2.79M Transaction-related and other non-recurring expenses
+$0K Loss (gain) on sale of assets
= Adjusted EBITDA $29.1M
|
|||
| Adjusted EBITDA Margin non-GAAP | 22.8% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Margin non-GAAP | 46.2% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit non-GAAP | $58.3M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP Gross Profit $45.49M
+$10.52M Depreciation and amortization included in cost of goods sold
+$709K Equity-based compensation included in cost of goods sold
+$1.57M Non-cash inventory adjustments
= Adjusted Gross Profit $58.29M
|
|||
| Free Cash Flow non-GAAP | $19.5M | Q2 2026 | — |
| Net Debt non-GAAP | $251.8M | Q2 2026 | — |
| Retail footprint | 55 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AAWH
this stock
Ascend Wellness Holdings, Inc.
|
$85.15M | -43.7% | -10.9% | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$64.50B | +27.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$49.23B | +1.9% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$46.52B | +30.2% | +4.3% | 65.4 | 2.6% |
|
HLN
Haleon plc
|
$44.06B | -0.9% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- HighPoint Advisor Group L…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AAWH | -7.2% | -29.9% | -29.1% | -24.4% | -43.7% |
| SPY | +0.5% | +0.7% | +7.6% | +1.4% | +13.4% |
| vs SPY | -7.7% | -30.6% | -36.7% | -25.8% | -57.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.